Somaiya Mayur Ian
Chief Financial Officer · 9 insider transactions on file
All transactions
| Date | Ticker | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-01-21 | NAMS | NewAmsterdam Pharma Co N.V. | Sale | 24,362 | $33.80 | $823,435.60 | filing |
| 2026-01-21 | NAMS | NewAmsterdam Pharma Co N.V. | Sale | 15,422 | $33.25 | $512,781.50 | filing |
| 2026-01-21 | NAMS | NewAmsterdam Pharma Co N.V. | Option exercise | 39,784 | $9.26 | $368,399.84 | filing |
| 2026-01-20 | NAMS | NewAmsterdam Pharma Co N.V. | Sale | 39,712 | $31.78 | $1.3M | filing |
| 2026-01-20 | NAMS | NewAmsterdam Pharma Co N.V. | Sale | 19,604 | $32.38 | $634,777.52 | filing |
| 2026-01-20 | NAMS | NewAmsterdam Pharma Co N.V. | Option exercise | 60,216 | $9.26 | $557,600.16 | filing |
| 2026-01-20 | NAMS | NewAmsterdam Pharma Co N.V. | Sale | 900 | $30.64 | $27,576.00 | filing |
| 2026-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Award | 25,500 | — | — | filing |
| 2026-01-05 | NAMS | NewAmsterdam Pharma Co N.V. | Sale | 5,118 | $33.25 | $170,173.50 | filing |
Insider transactions from SEC Form 4 filings via EDGAR. Names appear as filed and aren't normalized across issuers.